Brought to you by 
Seattle Genetics, Astellas ally with Merck in trial collaboration
16 Nov 2021
Executive Summary
| Seattle Genetics Inc. and Astellas Pharma Inc. are teaming up with Merck & Co. Inc. in a trial collaboration to evaluate the combination of Seattle Genetics/Astellas' enfortumab vedotin and Merck’s Keytruda (pembrolizumab) in patients with previously untreated metastatic urothelial cancer. |
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Seattle Genetics, Astellas ally with Merck in trial collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice